Drug discovery assays based on the biology of chronic disease

• US 20050255458A1
• Filed: 07/01/2003
• Published: 11/17/2005
• Est. Priority Date: 08/14/2002
• Status: Abandoned Application

• Current Assignee: Hanan Polansky
• Original Assignee: Hanan Polansky
• Inventors: Polansky, Hanan
• Application Number:
  US10/611,217
• Publication Number:
  US 20050255458A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites

Abstract

Using the recently discovered biology of chronic disease, the invention presents new methods for evaluating the effectiveness of a compound for use in modulating the progression of chronic disease, for determining whether a subject has a chronic disease, or has an increased risk of developing clinical symptoms associated with such disease, and for treating chronic disease.

Claims

1. A method for evaluating the ability of a compound to affect expression of a gene natural to a cell, the method comprising the steps of:

a. selecting a transcription complex natural to the cell, wherein the transcription complex is limiting;

b. selecting a polynucleotide foreign to the cell, wherein the foreign polynucleotide can bind the transcription complex;

c. selecting a compound of interest;

d. combining the compound with a system, wherein the system includes a known copy number of the foreign polynucleotide;

e. assaying the copy number of the foreign polynucleotide in the system after the combination; and

f. identifying whether the compound can modify the copy number.

2. The method of claim 1, wherein the cellular transcription complex includes a protein selected from the group consisting of p300 and cbp.

3. The method of claim 1, wherein the cellular transcription complex includes a GABP trans-acting regulatory protein.

4. The method of claim 1, wherein the foreign polynucleotide is a viral polynucleotide.

5. A method for evaluating an effectiveness of a compound for use in modulating progression of a disease, the method comprising the steps of:

a. selecting a transcription complex natural to a cell, wherein the transcription complex is limiting;

b. selecting a polynucleotide foreign to the cell, wherein the polynucleotide can bind the transcription complex;

c. selecting a compound of interest;

d. combining the compound with a system, wherein the system includes a known copy number of the foreign polynucleotide;

e. assaying the copy number of the foreign polynucleotide in the system after the combination; and

f. identifying whether the compound can modify the copy number.

6. The method of claim 5, wherein the cellular transcription complex includes a protein selected from the group consisting of p300 and cbp.

7. The method of claim 5 wherein the cellular transcription complex includes a GABP trans-acting regulatory protein

8. The method of claim 5, wherein the foreign polynucleotide is a viral polynucleotide.

9. The method of claim 5, wherein said chronic disease is selected from the group consisting of atherosclerosis, cancer, obesity, osteoarthritis, type II diabetes, type I diabetes, multiple sclerosis, asthma, lupus, thyroiditis, inflammatory bowel disease, rheumatoid arthritis, psoriasis, atopic dermatitis, graft versus host disease, and other autoimmune diseases.

10. A method for evaluating the ability of a compound to affect expression of a gene natural to a cell, the method comprising the steps of:

a. selecting a transcription complex natural to the cell, wherein the transcription complex is limiting;

b. selecting a polynucleotide foreign to the cell, wherein the foreign polynucleotide can bind the transcription complex;

c. selecting a compound of interest;

d. combining the compound with a system, wherein the system includes the transcription complex and the foreign polynucleotide;

e. assaying the complex between the transcription complex and the foreign polynucleotide in the system after the combination; and

f. identifying whether the compound can modify the complex between the transcription complex and the foreign polynucleotide.

11. The method of claim 10, wherein the cellular transcription complex includes a protein selected from the group consisting of p300 and cbp.

12. The method of claim 10, wherein the cellular transcription complex includes a GABP trans-acting regulatory protein.

13. The method of claim 10, wherein the foreign polynucleotide is a viral polynucleotide.

14. The method of claim 10, wherein the compound can modify the structure or the concentration of the complex between the transcription complex and the foreign polynucleotide.

15. A method for evaluating an effectiveness of a compound for use in modulating progression of a disease, the method comprising the steps of:

a. selecting a transcription complex natural to a cell, wherein the transcription complex is limiting;

b. selecting a polynucleotide foreign to the cell, wherein the foreign polynucleotide can bind the transcription complex;

c. selecting a compound of interest;

d. combining the compound with a system, wherein the system includes the transcription complex;

e. assaying the transcription complex in the system after the combination; and

f. identifying whether the compound can modify the transcription complex.

16. The method of claim 15, wherein the cellular transcription complex includes a protein selected from the group consisting of p300 and cbp.

17. The method of claim 15, wherein the cellular transcription complex includes a GABP trans-acting regulatory protein

18. The method of claim 15, wherein the foreign polynucleotide is a viral polynucleotide.

19. The method of claim 15, wherein the compound can modify the structure or concentration of the transcription complex.

20. The method of claim 15, wherein said chronic disease is selected from the group consisting of atherosclerosis, cancer, obesity, osteoarthritis, type II diabetes, type I diabetes, multiple sclerosis, asthma, lupus, thyroiditis, inflammatory bowel disease, rheumatoid arthritis, psoriasis, atopic dermatitis, graft versus host disease, and other autoimmune diseases.